Photopheresis Devices Market Size, Share, Growth, Trends, and Global Industry Analysis: By Product Type (Open System, Closed System), By Disease Indication (Autoimmune diseases, Graft versus host disease, Cutaneous T-cell lymphoma, Transplant rejections), By Distribution Channel (Hospitals, Ambulatory Care, Others) and By Region  

Photopheresis Devices Market was valued at US$ 267.78 million in 2023 and is anticipated to grow at US$ 397.35 million by end of 2030 growing at a CAGR of 5.9% during the forecast period 2024-2030.Photopheresis is a form of apheresis in which small amount of the blood is treated with photosensitizing agent. Photopheresis is popular for its therapeutic option used in various autoimmune diseases, organ transplantation such as kidney and liver advanced cutaneous T-cell lymphoma and acute and chronic graft versus host disease (GVHD). U.S. FDA in 1988, has first approved extracorporeal photopheresis (ECP) which is now known as extracorporeal photo immunotherapy, as leukapheresis-based therapeutic procedure.

In Photopheresis, the white blood cells are collected after being exposed to the UVA radiation, 8-MOP. As far as devices of photopheresis are concerned, many open and closed systems available in the market, of which only closed systems are approved by the U.S. FDA due to its lesser risk of contamination, flaws and infection during reinfusion. Photopheresis is a type of photodynamic therapy in which blood is treated with a blood sensitising chemical that has been exposed to a specific wavelength of light. Photopheresis products are in high demand all around the world. The rising incidence of autoimmune illnesses, as well as the rising number of organ transplant cases, are driving the global photopheresis products market. Growing health-care infrastructure, advancements in advanced technology, and an ageing population are all drivers that will propel the market forward.

Photopheresis Devices Market Key Developments:

• In August 2016, Mallinckrodt plc (NYSE: MNK), a leading specialty pharmaceutical company, announced that Switzerland's Federal Department of Home Affairs (FDHA) has approved reimbursement of Extracorporeal Photopheresis (ECP) treatment for patients in Switzerland with Bronchiolitis Obliterans Syndrome (BOS) following lung transplantation. Mallinckrodt Pharmaceuticals provides ECP therapy through its THERAKOS therapeutic platforms, including the latest generation THERAKOS CELLEX Photopheresis System